Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Submassive Pulmonary Embolism
Conditions
Submassive Pulmonary Embolism
Trial Timeline
Sep 1, 2004 → Jan 1, 2008
NCT ID
NCT00191724About Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) is a phase 2 stage product being developed by Eli Lilly for Submassive Pulmonary Embolism. The current trial status is completed. This product is registered under clinical trial identifier NCT00191724. Target conditions include Submassive Pulmonary Embolism.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00191724 | Phase 2 | Completed |